Global Plasma Protein Therapeutics Revenue Is Nearly 20 Billion USD In 2016
Friday, 26 Oct, 2018
In the last several years, global market of Plasma Protein Therapeutics developed rapidly, with an average growth rate of 7.1%. In 2016, global revenue of Plasma Protein Therapeutics is nearly 20 billion USD.
The classification of Plasma Protein Therapeutics includes Coagulation Factor, Immune Globulin, Albumin and Other, The production revenue of Coagulation Factor 3900 M USD, with its revenue market share 19.5%. And the production revenue market share of Immune Globulin is 50.7% in 2016.
Plasma Protein Therapeutics is widely used to treat Hemophilia, PID and Other. The most proportion of Plasma Protein Therapeutics is to treat PID, and the proportion is about 35.5% in 2016.
North America region is the largest supplier of Plasma Protein Therapeutics, with a revenue market share nearly 60% in 2016. Europe is the second largest supplier of Plasma Protein Therapeutics, enjoying revenue market share nearly 18.3% in 2016.
North America is the largest sales place, with a consumption value market share nearly 40% in 2016. Following North America, Europe is the second largest sales place with the sales market share of 25.9% in 2016. China is an important market of Blood Product in Asia, accounting for 9% production revenue market share and 14% sales revenue market share of global market.
That is to say, there are a large number of exports in North America, while North America also is the largest consumption region.
Baxter, CSL, Grifols are the leaders of the industry, with 70% market share in 2016, and hold key technologies and patents. Other manufactures’ products are used to meet local demand. With further expanding market, there will be more players in the future.